Background Clinical or subclinical cardiotoxicity is a concern for cancer patients receiving
anthracycline-based chemotherapy. Carvedilol is promising for preventing anthracycline …

Throughout the last decades, newly developed chemotherapeutic agents and
immunotherapies that target signaling pathways have provided patients with better …

The study of mechanisms underlying cardiotoxicity of doxorubicin and the development of
strategies to mitigate doxorubicin-induced cardiotoxicity are the most relevant issues of …

Cancer is one of the leading causes of deaths worldwide with 18.1 million deaths per year.
Although there have been significant advances in anti-cancer therapies, they can often …

Background and Purpose The clinical use of doxorubicin, an effective anticancer drug, is
severely hampered by its cardiotoxicity. 23‐H ydroxybetulinic acid (23‐HBA), isolated from P …

Herbal medicines are represented as the most potential field of alternative medicines all
over the world for a number of diseases in which allopathic medicines have no or little …

Background The clinical use of Doxorubicin (Dox) is significantly limited by its dose-
dependent cardiotoxic side effect. Accumulative evidence suggests that the use of …

Based on the World Health Organization (WHO) report, in many of the countries, cancer was
the first or second most cause for death before 70 years of the age. Nowadays cancer …

Background There is no proven primary preventive strategy for doxorubicin‐induced
subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) …

Cancer is a major public health problem, and chemotherapy plays a significant role in the
management of neoplastic diseases. However, chemotherapy-induced cardiotoxicity is a …